


CLAIMS

1. An amine salt of a carbostyryl derivative formed from a carbostyryl derivative represented by the formula (1):



wherein:

R is a halogen atom,

the substituted position of the side chain is 3- or 4-position in the carbostyryl skeleton, and

10 the bonding between 3- and 4-positions of the carbostyryl skeleton is a single bond or a double bond, and an amine.

2. The amine salt of the carbostyryl derivative according to claim 1, wherein said carbostyryl derivative (1) is 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid.

15

3. The amine salt of the carbostyryl derivative according to claim 2, wherein said amine is L-arginine.

4. The amine salt of the carbostyryl derivative according to claim 2, wherein said amine is L-lysine.

20 5. The amine salt of the carbostyryl derivative according to claim 2, wherein said amine is ethylenediamine.

6. The amine salt of the carbostyryl derivative according to claim 2, wherein said amine is tris(hydroxymethyl)-

aminomethane.

7. The amine salt of the carbostyryl derivative according to claim 2, wherein said amine is monoethanolamine.


8. The amine salt of the carbostyryl derivative according to claim 2, wherein said amine is diethanolamine.

9. The amine salt of the carbostyryl derivative according to claim 2, wherein said amine is diisopropanolamine.

10. The amine salt of the carbostyryl derivative according to claim 2, wherein said amine is meglumine.

11. A pharmaceutical formulation comprising the amine salt of the carbostyryl derivative according to any one of claims 1 - 10 as the active ingredient.

12. A pharmaceutical formulation which is prepared in the form of an aqueous solution by adding an aqueous solvent when used, comprising a carbostyryl derivative represented by the formula (1):



wherein:

R is a halogen atom,

the substituted position of the side chain is 3- or 4-position in the carbostyryl skeleton, and

the bonding between 3- and 4-positions of the carbostyryl skeleton is a single bond or a double bond,

and an amine.

13. The pharmaceutical formulation to be prepared in a preparation when used according to claim 12, wherein said carbostyryl derivative (1) is 2-(4-chlorobenzoylamino)-3-
5 (2-quinolon-4-yl)propionic acid.

14. The pharmaceutical formulation to be prepared in a preparation when used according to claim 13, wherein said amine is L-arginine.

15. The pharmaceutical formulation to be prepared in a preparation when used according to claim 13, wherein said
10 amine is L-lysine..

16. The pharmaceutical formulation to be prepared in a preparation when used according to claim 13, wherein said amine is ethylenediamine.

15 17. The pharmaceutical formulation to be prepared in a preparation when used according to claim 13, wherein said amine is tris(hydroxymethyl)aminomethane.

18. The pharmaceutical formulation to be prepared in a preparation when used according to claim 13, wherein said
20 amine is monoethanolamine.

19. The pharmaceutical formulation to be prepared in a preparation when used according to claim 13, wherein said amine is diethanolamine.

20. The pharmaceutical formulation to be prepared in a preparation when used according to claim 13, wherein said
25

amine is diisopropanolamine.

21. The pharmaceutical formulation to be prepared in a preparation when used according to claim 13, wherein said amine is meglumine.